journal article Open Access Mar 31, 2010

Plasma Growth Differentiation Factor-15 Independently Predicts All-Cause and Cardiovascular Mortality As Well As Deterioration of Kidney Function in Type 1 Diabetic Patients With Nephropathy

View at Publisher Save 10.2337/dc09-2174
Abstract
OBJECTIVE
Growth deferentiation factor-15 (GDF-15) is involved in inflammation and apoptosis. Expression is induced in the heart in response to ischemia and in atherosclerotic plaques. The aim of this study was to investigate GDF-15 levels in relation to all-cause mortality, cardiovascular mortality and morbidity, decline in glomerular filtration rate (GFR), and progression toward end-stage renal disease (ESRD).


RESEARCH DESIGN AND METHODS
The study was a prospective observational follow-up study including 451 type 1 diabetic patients with diabetic nephropathy (274 men, aged 42.1 ± 0.5 years [means ± SD], diabetes duration 28.3 ± 8.9 years, GFR 76 ± 33 ml/min/1.73 m2) and a control group of 440 patients with longstanding type 1 diabetes and persistent normoalbuminuria (232 men, aged 45.4 ± 11.5 years, duration of diabetes 27.7 ± 10.1 years). The patients were followed for 8.1 (0.0–12.9) years (median [range]).


RESULTS
Among normoalbuminuric patients, GDF-15 above the median predicted an adjusted (age, systolic blood pressure [sBP], and estimated GFR) increased risk of all-cause mortality (hazard ratio [HR] 3.6 [95% CI 1.3–10.3]; P = 0.014). Among patients with diabetic nephropathy, higher (fourth quartile) versus lower (first quartile) GDF-15 levels predict all-cause mortality (covariate-adjusted [sex, age, smoking, blood pressure, A1C, cholesterol, GFR, N-terminal prohormone B-type natriuretic peptide, antihypertensive treatment, and previous cardiovascular events]; HR 4.86 [95% CI 1.37–17.30]) as well as fatal and nonfatal cardiovascular events (adjusted HR 5.59 [1.23–25.43] and 3.55 [1.08–11.64], respectively). In addition, higher GDF-15 levels predict faster decline in GFR (P < 0.001) but not development of ESRD.


CONCLUSIONS
Higher levels of GDF-15 are a predictor of all-cause and cardiovascular mortality and morbidity in patients with diabetic nephropathy. Furthermore, higher levels of GDF-15 are associated with faster deterioration of kidney function.
Topics

No keywords indexed for this article. Browse by subject →

References
25
[1]
Rossing "Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study" BMJ (1996) 10.1136/bmj.313.7060.779
[2]
Kannel "Incidence and epidemiology of heart failure" Heart Fail Rev (2000) 10.1023/a:1009884820941
[3]
Lloyd-Jones "Lifetime risk for developing congestive heart failure: the Framingham Heart Study" Circulation (2002) 10.1161/01.cir.0000039105.49749.6f
[4]
Selvetella "Adaptive and maladaptive hypertrophic pathways: points of convergence and divergence" Cardiovasc Res (2004) 10.1016/j.cardiores.2004.04.031
[5]
Azhar "Transforming growth factor beta in cardiovascular development and function" Cytokine Growth Factor Rev (2003) 10.1016/s1359-6101(03)00044-3
[6]
Molkentin "A friend within the heart: natriuretic peptide receptor signaling" J Clin Invest (2003) 10.1172/jci18389
[7]
Strelau "GDF-15/MIC-1: a novel member of the TGF-beta superfamily" J Neural Transm (2000)
[8]
Bootcov "MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily" Proc Natl Acad Sci U S A (1997) 10.1073/pnas.94.21.11514
[9]
Kempf "The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury" Circ Res (2006) 10.1161/01.res.0000202805.73038.48
[10]
GDF15/MIC-1 Functions As a Protective and Antihypertrophic Factor Released From the Myocardium in Association With SMAD Protein Activation

Jian Xu, Thomas R. Kimball, John N. Lorenz et al.

Circulation Research 2006 10.1161/01.res.0000202804.84885.d0
[11]
Schlittenhardt "Involvement of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in oxLDL-induced apoptosis of human macrophages in vitro and in arteriosclerotic lesions" Cell Tissue Res (2004) 10.1007/s00441-004-0986-3
[12]
Brown "Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study" Lancet (2002) 10.1016/s0140-6736(02)09093-1
[13]
Kempf "Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction" Eur Heart J (2007) 10.1093/eurheartj/ehm465
[14]
Wollert "Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome" Circulation (2007) 10.1161/circulationaha.106.650846
[15]
Tarnow "European rational approach for the genetics of diabetic complications–EURAGEDIC: patient populations and strategy" Nephrol Dial Transplant (2008) 10.1093/ndt/gfm501
[16]
Bröchner-Mortensen "Selection of routine method for determination of glomerular filtration rate in adult patients" Scand J Clin Lab Invest (1976) 10.1080/00365517609068016
[17]
National Kidney Foundation "K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification" Am J Kidney Dis (2002)
[18]
Kempf "Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay" Clin Chem (2007) 10.1373/clinchem.2006.076828
[19]
Tarnow "Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy" Diabetologia (2005) 10.1007/s00125-004-1595-0
[20]
Oliver "Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A" Proc Natl Acad Sci U S A (1997) 10.1073/pnas.94.26.14730
[21]
Olsen "N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study" J Hypertens (2004) 10.1097/01.hjh.0000125451.28861.2a
[22]
Madsen "N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis" Kidney Int (2007) 10.1038/sj.ki.5002087
[23]
Gaede "Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria" Diabetologia (2005) 10.1007/s00125-004-1607-0
[24]
Wollert "Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome" Circulation (2007) 10.1161/circulationaha.107.697714
[25]
Preusch "Bone marrow derived growth differentiation factor-15 (GDF-15) protects from macrophage accumulation and effects atherosclerotic lesion stabilisation in low-density lipoprotein receptor-null mice" Circulation (2008) 10.1161/circ.118.suppl_18.s_511-c
Cited By
114
The GDF15-GFRAL axis mediates chemotherapy-induced fatigue in mice

Brandon Chelette, Chinenye L. Chidomere · 2023

Brain, Behavior, and Immunity
Growth Differentiation Factor–15 and Risk of CKD Progression

Viji Nair, Cassianne Robinson-Cohen · 2017

Journal of the American Society of...
Metrics
114
Citations
25
References
Details
Published
Mar 31, 2010
Vol/Issue
33(7)
Pages
1567-1572
License
View
Cite This Article
Maria Lajer, Anders Jorsal, Lise Tarnow, et al. (2010). Plasma Growth Differentiation Factor-15 Independently Predicts All-Cause and Cardiovascular Mortality As Well As Deterioration of Kidney Function in Type 1 Diabetic Patients With Nephropathy. Diabetes Care, 33(7), 1567-1572. https://doi.org/10.2337/dc09-2174